|
|
 Previous Article | Table of Contents | Next Article 
Blood, 1 November 2000, Vol. 96, No. 9, pp. 3139-3146
NEOPLASIA
High levels of soluble syndecan-1 in myeloma-derived bone
marrow: modulation of hepatocyte growth factor activity
Carina Seidel,
Magne Børset,
Øyvind Hjertner,
Dianjun Cao,
Niels Abildgaard,
Henrik Hjorth-Hansen,
Ralph D. Sanderson,
Anders Waage, and
Anders Sundan
From the Institute of Cancer Research and
Molecular Biology, Norwegian University of Science and Technology,
Trondheim, Norway; the Department of Pathology, Arkansas Cancer
Research Center, Little Rock, AR; the Section of Hematology, Aarhus
University Hospital, Aarhus, Denmark; and the Section of Hematology,
Institute of Environmental Medicine, University Hospital, Trondheim,
Norway.
Syndecan-1 is a heparan sulfate proteoglycan expressed on the
surface of, and actively shed by, myeloma cells. Hepatocyte growth
factor (HGF) is a cytokine produced by myeloma cells. Previous studies
have demonstrated elevated levels of syndecan-1 and HGF in the serum of
patients with myeloma, both of negative prognostic value for the
disease. Here we show that the median concentrations of syndecan-1 (900 ng/mL) and HGF (6 ng/mL) in the marrow compartment of patients with
myeloma are highly elevated compared with healthy controls and controls
with other diseases. We show that syndecan-1 isolated from the marrow
of patients with myeloma seems to exist in an intact form, with
glucosaminoglycan chains. Because HGF is a heparan-sulfate binding
cytokine, we examined whether it interacted with soluble syndecan-1. In
supernatants from myeloma cells in culture as well as in pleural
effusions from patients with myeloma, HGF existed in a complex with
soluble syndecan-1. Washing myeloma cells with purified soluble
syndecan-1 could effectively displace HGF from the cell surface,
suggesting that soluble syndecan-1 can act as a carrier for HGF in
vivo. Finally, using a sensitive HGF bioassay (interleukin-11
production from the osteosarcoma cell line Saos-2) and intact
syndecan-1 isolated from the U-266 myeloma cell line, we found that the
presence of high concentrations of syndecan-1 (more than 3 µg/mL)
inhibited the HGF effect, whereas lower concentrations potentiated it.
HGF is only one of several heparin-binding cytokines associated with
myeloma. These data indicate that soluble syndecan-1 may participate in
the pathology of myeloma by modulating cytokine activity within the
bone marrow.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
R. U. Holt, U.-M. Fagerli, V. Baykov, T. B. Ro, H. Hov, A. Waage, A. Sundan, and M. Borset
Hepatocyte growth factor promotes migration of human myeloma cells
Haematologica,
April 1, 2008;
93(4):
619 - 622.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Standal, N. Abildgaard, U.-M. Fagerli, B. Stordal, O. Hjertner, M. Borset, and A. Sundan
HGF inhibits BMP-induced osteoblastogenesis: possible implications for the bone disease of multiple myeloma
Blood,
April 1, 2007;
109(7):
3024 - 3030.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. D. Theocharis, C. Seidel, M. Borset, K. Dobra, V. Baykov, V. Labropoulou, I. Kanakis, E. Dalas, N. K. Karamanos, A. Sundan, et al.
Serglycin Constitutively Secreted by Myeloma Plasma Cells Is a Potent Inhibitor of Bone Mineralization in Vitro
J. Biol. Chem.,
November 17, 2006;
281(46):
35116 - 35128.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Kelly, L. J. Suva, Y. Huang, V. MacLeod, H.-Q. Miao, R. C. Walker, and R. D. Sanderson
Expression of Heparanase by Primary Breast Tumors Promotes Bone Resorption in the Absence of Detectable Bone Metastases
Cancer Res.,
July 1, 2005;
65(13):
5778 - 5784.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Mikaelsson, A. H. Danesh-Manesh, A. Luppert, M. Jeddi-Tehrani, M.-R. Rezvany, R. A. Sharifian, R. Safaie, A. Roohi, A. Osterborg, F. Shokri, et al.
Fibromodulin, an extracellular matrix protein: characterization of its unique gene and protein expression in B-cell chronic lymphocytic leukemia and mantle cell lymphoma
Blood,
June 15, 2005;
105(12):
4828 - 4835.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Hov, R. U. Holt, T. B. Ro, U.-M. Fagerli, H. Hjorth-Hansen, V. Baykov, J. G. Christensen, A. Waage, A. Sundan, and M. Borset
A Selective c-Met Inhibitor Blocks an Autocrine Hepatocyte Growth Factor Growth Loop in ANBL-6 Cells and Prevents Migration and Adhesion of Myeloma Cells
Clin. Cancer Res.,
October 1, 2004;
10(19):
6686 - 6694.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Kelly, H.-Q. Miao, Y. Yang, E. Navarro, P. Kussie, Y. Huang, V. MacLeod, J. Casciano, L. Joseph, F. Zhan, et al.
High Heparanase Activity in Multiple Myeloma Is Associated with Elevated Microvessel Density
Cancer Res.,
December 15, 2003;
63(24):
8749 - 8756.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Standal, C. Seidel, O. Hjertner, T. Plesner, R. D. Sanderson, A. Waage, M. Borset, and A. Sundan
Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells
Blood,
September 26, 2002;
100(8):
3002 - 3007.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Yang, S. Yaccoby, W. Liu, J. K. Langford, C. Y. Pumphrey, A. Theus, J. Epstein, and R. D. Sanderson
Soluble syndecan-1 promotes growth of myeloma tumors in vivo
Blood,
June 28, 2002;
100(2):
610 - 617.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A.-T. Brenne, T. Baade Ro, A. Waage, A. Sundan, M. Borset, and H. Hjorth-Hansen
Interleukin-21 is a growth and survival factor for human myeloma cells
Blood,
May 15, 2002;
99(10):
3756 - 3762.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. W. B. Derksen, R. M. J. Keehnen, L. M. Evers, M. H. J. van Oers, M. Spaargaren, and S. T. Pals
Cell surface proteoglycan syndecan-1 mediates hepatocyte growth factor binding and promotes Met signaling in multiple myeloma
Blood,
February 15, 2002;
99(4):
1405 - 1410.
[Abstract]
[Full Text]
[PDF]
|
|
|
| |
